The anaphylaxis treatment landscape is evolving. neffy®, the new epinephrine nasal spray*, is now available in Canada, providing healthcare professionals with a new option for their patients. Join the expert-led webinar to learn more.
What you need to know
A new option in anaphylaxis management
What to expect during this LIVE webinar
This webinar will explore clinical studies of neffy®, the new epinephrine nasal spray* in Canada, along with practical considerations and expert perspectives on evolving approaches to anaphylaxis management. During the session, you will:
- Deepen your understanding of the unmet patient needs that can delay timely anaphylaxis treatment.
- Explore key clinical PK and PD data, and safety profile for an epinephrine nasal spray and their potential relevance to real-world care.
- Discover practical considerations for supporting patients in your practice who may benefit from a non-injectable treatment option.
- Gain valuable clinical insights from experts to help guide discussions with your own patients.
- Engage directly with expert faculty during a live Q&A session.
Device shown is not actual size
*neffy® is indicated for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis in adult and pediatric patients who weigh 30 kg or greater. Comparative clinical significance has not been established.
Meet your speaker
Dr. Jason Lee
MD allergy and immunology
Chief Executive Officer of Evidence Based Medical Educator, Inc., and Founder and Chair of Urticaria Canada, Dr. Lee earned his MD from the University of Toronto and completed fellowships in internal medicine at the University of British Columbia and in clinical immunology and allergy at the University of Toronto.
Who should attend?
Any healthcare professional managing patients with type 1 allergy, including those at risk of anaphylaxis.
Pediatricians
Nurse Practitioners
ER Physicians
Family Physicians
Pharmacists
Paramedic
Can’t make it to the webinar?
Register anyway, and we’ll send you a summary of key takeaways and supplemental resources to review on your own time.
Device shown is not actual size
* neffy® is indicated for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis in adult and pediatric patients who weigh 30 kg or greater. Comparative clinical significance has not been established.
PK, pharmacokinetics; PD, pharmacodynamics.
Join our LIVE webinar on 27 October, 2026
Are you registered with IQVIA OneKey Connect?
Don’t have an account yet? Sign up here.
CA-neff-2600087